Skip to main content

Revisiting Vioxx: Monitoring Future Drugs Post Approval

SYNTHESIS of: Press Release, Penn Medicine News. “NSAIDs and Cardiovascular Risk Explained, According to Studies from the Perelman School of Medicine,” May 2, 2012; and “FDA Must Be Proactive About Postapproval Drug Safety: IOM,” May 3, 2012, Medscape


Nearly 10 years after Merck withdrew the COX-2 inhibitor Vioxx® (rofecoxib) from the market in 2004 because it increased the risk of heart problems when used for over one year, eight randomized trials conducted by researchers at the University of Pennsylvania Perelman School of Medicine confirmed the possible adverse side effects of COX-2 inhibitors like Vioxx®.
Initially, COX-2 inhibitors were viewed as a better alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs) like Advil because they are less likely to cause gastrointestinal bleeding.
Vioxx® selectively blocks COX-2, which produces prostaglandins (specifically prostocyclin) that cause pain and inflammation. However, prostocyclin also acts as an anticoagulant and relaxes blood vessels. In mice populations, removing COX-2 resulted in high blood pressure and blood clotting. An investigative team led by Penn’s Garret FitzGerald, MD, chair of the department of Pharmacology and Director for Translational Medicine and Therapeutics, had already noted that both Celebrex® (celecoxib) and Vioxx® inhibit prostocyclin in humans.
            Other COX-2 inhibitors such as Bextra® (valdecoxib), Arcoxia® (etoricoxib), and Celebrex® have either been removed from the market, failed to attain Federal Drug Administration (FDA) approval, or are accompanied by a warning label.
It is important to note that the risk of having a cardiac event after 18 months of taking Vioxx compared to subjects taking a placebo is 1.9%, or double the risk, still small by FDA standards. Merck identified the increased risk in its own post-market study but was not permitted to publicize them due to FDA labeling restrictions.
Penn’s recent research does include new findings that may have implications for patients without preexisting heart disease. In mice, inhibition of COX-2 led to hardening of the arteries. Based on this, researchers predict that the use of COX inhibitors in healthy subjects can raise the risk of events such as heart attack or stroke to that of diabetics or smokers. Patients with preexisting heart disease are still most at risk.
The Institute of Medicine (IOM), an independent, nonprofit organization, believes it knows how the FDA can take a proactive stance on potential adverse effects that may emerge during the post-approval stage. Most exploratory research is done before a product hits the market, not after. In an effort to resolve this dilemma, the IOM, in a report entitled “Ethical and Scientific Issues in Studying the Safety of Approved Drugs” (May 1, 2012), recommended that the FDA develop a system to track the safety of drugs after they have been approved. The guidelines come in the wake of several drugs that encountered problems after they had been approved for use, such as Vioxx®.
In 2007, the passage of the FDA Amendments Act (FDAAA) strengthened the FDA’s ability to track post-market drug safety. Before the Act was passed, the agency could only withdraw the product from the market or instruct the manufacturer to alter the label or add warnings. Now, a monitoring system designed to beef up the FDAAA has been created. Known as BRAMP (benefit and risk assessment and management plan), it will monitor benefits and risks during the entire “life cycle” of a drug.
The IOM highlights a key question: should research be conducted on subjects after the drug is already on the market in order to test the effects of the drug in specific sub-populations that may have different benefit-risk profiles than those in the initial clinical trials? The IOM advocates the same strict adherence to ethical guidelines that applies to post-market testing.
The million-dollar question left unanswered by the IOM is who will foot the bill for the additional monitoring and research: will it be Uncle Sam or the pharmaceutical industry?

Comments

Post a Comment

Popular posts from this blog

Frank Bender: Local Artist Who Became a Forensic Phenomenon

“If Frank does your bust, you’re toast.” (John Walsh, former host of the long-running television show  America’s Most Wanted ) Although the mustard-yellow building located at 2215 South Street next to Bicycle Therapy now houses an art gallery, from 1986 until his death in 2011, Francis (Frank) Augustus Bender, Jr. lived and worked in this small space. He was first known as a talented painter and sculptor, but in the late 1970s, he embarked on a second career in which he helped local and national law enforcement officials to identify victims of violent crime and to track down individuals who had managed to elude justice for years and even decades. Fascinated with human anatomy, Bender regularly visited Philadelphia’s morgue to learn more about this topic by viewing corpses. After examining a woman whose features had been obliterated by multiple gunshot wounds, Bender boldly declared that he knew what the victim’s face looked like before her injuries. Although he helped ...
Post a Comment
Read more

The Emotionally Fraught World of the Turkish Language

My Turkish mother did not speak her native language with my sister and I during our childhood lest it prevented us from attaining fluency in our native tongue. Linguistic research has proved my mother wrong. She did, however, often take us to visit our grandparents and other relatives in Ankara,Izmir, and Istanbul almost annually. Before and during our trips, I took self-administered language courses whose curriculums consisted of poorly written instructional books. If only I had had an app like Duolingo back in the 80s, I’d be fluent by now. My studying didn’t go very far. My younger sister Katie and I would commiserate with one another (in English) on the conversational sidelines as my mom engaged in animated dialogue with her many relatives. “They might as well be  barking ,” I complained.  The barrier was felt to be THAT great. “The goat is in the box” became a treasured phrase, but not one likely to prove useful. (Humorous aside: my closest encounter with farm animal...
Post a Comment
Read more

Blackfish (2013)

Watching  Blackfish  reminded me of the scene in the first season of  The Walking Dead  in which Rick rides a beautiful chestnut horse into Atlanta. He has no idea that he is entering a dead zone of utter destruction and chaos. The viewer soon recognizes that he has placed a beautiful, noble animal—and himself—in peril. The horse is visibly terrified by the smell of death. Zombies attack almost immediately. They tear apart its flesh, devouring it while Rick beats a hasty retreat into a nearby tank. This is the one scene in all four seasons of the series that I dread. Of course, there are countless human victims in the show, but there’s something special about animals that touches our souls. Killer whales have a rich, inner emotional life that neuroscientists and animal behaviorists have observed. They communicate through a complex series of sounds that together form a type of language. In the wild, they travel in families, or pods. The children of a female killer ...
Post a Comment
Read more